83 related articles for article (PubMed ID: 25399009)
21. HER2 overexpression increases sensitivity to gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, through inhibition of HER2/HER3 heterodimer formation in lung cancer cells.
Hirata A; Hosoi F; Miyagawa M; Ueda S; Naito S; Fujii T; Kuwano M; Ono M
Cancer Res; 2005 May; 65(10):4253-60. PubMed ID: 15899817
[TBL] [Abstract][Full Text] [Related]
22. Single-molecule study of lateral mobility of epidermal growth factor receptor 2/HER2 on activation.
Xiao Z; Ma X; Jiang Y; Zhao Z; Lai B; Liao J; Yue J; Fang X
J Phys Chem B; 2008 Apr; 112(13):4140-5. PubMed ID: 18324805
[TBL] [Abstract][Full Text] [Related]
23. Epiregulin binds to epidermal growth factor receptor and ErbB-4 and induces tyrosine phosphorylation of epidermal growth factor receptor, ErbB-2, ErbB-3 and ErbB-4.
Komurasaki T; Toyoda H; Uchida D; Morimoto S
Oncogene; 1997 Dec; 15(23):2841-8. PubMed ID: 9419975
[TBL] [Abstract][Full Text] [Related]
24. The ErbB/HER family of protein-tyrosine kinases and cancer.
Roskoski R
Pharmacol Res; 2014 Jan; 79():34-74. PubMed ID: 24269963
[TBL] [Abstract][Full Text] [Related]
25. The interplay of HER2/HER3/PI3K and EGFR/HER2/PLC-γ1 signalling in breast cancer cell migration and dissemination.
Balz LM; Bartkowiak K; Andreas A; Pantel K; Niggemann B; Zänker KS; Brandt BH; Dittmar T
J Pathol; 2012 Jun; 227(2):234-44. PubMed ID: 22262199
[TBL] [Abstract][Full Text] [Related]
26. TOB1 is regulated by EGF-dependent HER2 and EGFR signaling, is highly phosphorylated, and indicates poor prognosis in node-negative breast cancer.
Helms MW; Kemming D; Contag CH; Pospisil H; Bartkowiak K; Wang A; Chang SY; Buerger H; Brandt BH
Cancer Res; 2009 Jun; 69(12):5049-56. PubMed ID: 19491269
[TBL] [Abstract][Full Text] [Related]
27. Impact of common epidermal growth factor receptor and HER2 variants on receptor activity and inhibition by lapatinib.
Gilmer TM; Cable L; Alligood K; Rusnak D; Spehar G; Gallagher KT; Woldu E; Carter HL; Truesdale AT; Shewchuk L; Wood ER
Cancer Res; 2008 Jan; 68(2):571-9. PubMed ID: 18199554
[TBL] [Abstract][Full Text] [Related]
28. Structural basis for eliciting a cytotoxic effect in HER2-overexpressing cancer cells via binding to the extracellular domain of HER2.
Jost C; Schilling J; Tamaskovic R; Schwill M; Honegger A; Plückthun A
Structure; 2013 Nov; 21(11):1979-91. PubMed ID: 24095059
[TBL] [Abstract][Full Text] [Related]
29. Roles of BIM induction and survivin downregulation in lapatinib-induced apoptosis in breast cancer cells with HER2 amplification.
Tanizaki J; Okamoto I; Fumita S; Okamoto W; Nishio K; Nakagawa K
Oncogene; 2011 Sep; 30(39):4097-106. PubMed ID: 21499301
[TBL] [Abstract][Full Text] [Related]
30. Physicochemical characterization of the cytoplasmic domain of the epidermal growth factor receptor and evidence for conformational changes associated with its activation by ammonium sulphate.
Gregoriou M; Jones PF; Timms JF; Yang JJ; Radford SE; Rees AR
Biochem J; 1995 Mar; 306 ( Pt 3)(Pt 3):667-78. PubMed ID: 7702558
[TBL] [Abstract][Full Text] [Related]
31. Identification of autophosphorylation sites of HER2/neu.
Hazan R; Margolis B; Dombalagian M; Ullrich A; Zilberstein A; Schlessinger J
Cell Growth Differ; 1990 Jan; 1(1):3-7. PubMed ID: 1706616
[TBL] [Abstract][Full Text] [Related]
32. Tob-mediated cross-talk between MARCKS phosphorylation and ErbB-2 activation.
Jin Cho S; La M; Ahn JK; Meadows GG; Joe CO
Biochem Biophys Res Commun; 2001 May; 283(2):273-7. PubMed ID: 11327693
[TBL] [Abstract][Full Text] [Related]
33. Extramammary Paget's disease: analysis of growth signal pathway from the human epidermal growth factor receptor 2 protein.
Ogawa T; Nagashima Y; Wada H; Akimoto K; Chiba Y; Nagatani T; Inayama Y; Yao M; Aoki I; Ikezawa Z
Hum Pathol; 2005 Dec; 36(12):1273-80. PubMed ID: 16311120
[TBL] [Abstract][Full Text] [Related]
34. Investigating Molecular Mechanisms of Activation and Mutation of the HER2 Receptor Tyrosine Kinase through Computational Modeling and Simulation.
Telesco SE; Shih A; Liu Y; Radhakrishnan R
Cancer Res J; 2011; 4(4):1-35. PubMed ID: 25346782
[TBL] [Abstract][Full Text] [Related]
35. Role of HER2/HER3 co-receptor in breast carcinogenesis.
Way TD; Lin JK
Future Oncol; 2005 Dec; 1(6):841-9. PubMed ID: 16556064
[TBL] [Abstract][Full Text] [Related]
36. A conformationally constrained peptidomimetic binds to the extracellular region of HER2 protein.
Banappagari S; Ronald S; Satyanarayanajois SD
J Biomol Struct Dyn; 2010 Dec; 28(3):289-308. PubMed ID: 20919746
[TBL] [Abstract][Full Text] [Related]
37. Evaluation of active recombinant catalytic domain of human ErbB-2 tyrosine kinase, and suppression of activity by a naturally derived inhibitor, ZH-4B.
Guo XN; Zhong L; Zhang XH; Zhao WM; Zhang XW; Lin LP; Ding J
Biochim Biophys Acta; 2004 Aug; 1673(3):186-93. PubMed ID: 15279890
[TBL] [Abstract][Full Text] [Related]
38. c-erbB-2/EGFR as dominant heterodimerization partners determine a motogenic phenotype in human breast cancer cells.
Brandt BH; Roetger A; Dittmar T; Nikolai G; Seeling M; Merschjann A; Nofer JR; Dehmer-Möller G; Junker R; Assmann G; Zaenker KS
FASEB J; 1999 Nov; 13(14):1939-49. PubMed ID: 10544177
[TBL] [Abstract][Full Text] [Related]
39. Conformational analysis of the phosphorylated epidermal growth factor receptor.
Bishayee A; Beguinot L; Bishayee S
Biosci Rep; 1999 Oct; 19(5):397-402. PubMed ID: 10763807
[TBL] [Abstract][Full Text] [Related]
40. Tailoring chimeric ligands for studying and biasing ErbB receptor family interactions.
Krueger AT; Kroll C; Sanchez E; Griffith LG; Imperiali B
Angew Chem Int Ed Engl; 2014 Mar; 53(10):2662-6. PubMed ID: 24481645
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
